Janssen

Johnson & Johnson (NYSE: JNJ) released much-awaited top-line results Friday from a large scale, late-stage study of its coronavirus vaccine candidate. The data hasn't gone down well with investors, with the shares of the health care company ticking lower in the session. ...

Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) were advancing strongly Thursday following a clinical trial update from the company. What Happened: AC Immune announced positive interim tolerability and immunogenicity results from the initial dosing group in a Phase 1b/2a...

When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment. But by that point, it may be too late for intervention. These diseases can silently do irreversible damage, according to Provention Bio Inc (NASDAQ: PRVB) CEO...

Immunomedics, Inc. (NASDAQ: IMMU) is a biopharma company focusing on the development of antibody-drug conjugates, or ADCs. The Morris Plains, New Jersey-based company was founded in 1982 and has yet to market a commercial product.  Its investigational therapies include ADCs that are...

Geron Corporation (NASDAQ: GERN), which is given to volatility due to heavy short interest, made a wild swing to the downside Thursday. What Happened Geron announced ahead of the market open that Johnson & Johnson (NYSE: JNJ)'s Janssen unit has decided to terminate a...

Neos Therapeutics Inc (NASDAQ: NEOS) shares began tumbling on June 20, despite announcing late on June 19 that the FDA approved its Cotempla XR-ODT, a methylphenidate extended-release orally disintegrating tablet for treating attention-deficit/hyperactivity disorder in patients aged 6–17...

BTIG expects Geron Corporation (NASDAQ: GERN) shares to be range-bound until major data release, potentially in late 2017 or 2018. Geron's lead compound imetelstat, an inhibitor of telomerase partnered with Johnson & Johnson (NYSE: JNJ)'s Janssen showed impressive activity in multiple...

Incontact Inc (NASDAQ: SAAS): +53.77 percent Announcement that it was acquired by Israeli peer Nice-Systems Ltd (ADR) (NASDAQ: NICE) for $940 million Great Basin Scientific Inc (NASDAQ: GBSN): +73.99 percent Initiating clinical trial for Bordatella and application to the FDA for direct test in Q4...